They're "linking the product.... with product which will be used in the proposed... trial in adults".
There's no point in this without data from the adult trial.
I admit, as usual they've worded it in a very obscure way.
But how do you explain it otherwise? What would be the use of comparing potency of previous cells to some that will be used in the future but haven't yet, as justification to approve the child indication based on data from the previous cells?
That interpretation is nonsense. If you don't believe me,
as usual, time will tell.
Ann: Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial, page-41
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |